drugset / Trial / NCT07328854
40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma
RandomizedParallel-groupOpen-labelTreatment
Summary
This study aims to explore the efficacy and adverse events of reduced-dose radiotherapy (40.2Gy) versus conventional-dose radiotherapy (49.2Gy) to low-risk target volume for chemosensitive intermediate-stage nasopharyngeal carcinoma patients.
Timeline
- Start
- 2025-11-20
- Primary completion
- 2030-06-30
- Completion
- 2032-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Cisplatin | Other / unclassified | 80 mg/m2 | Intravenous |
| Background | Docetaxel | Small molecule | — | — |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Background | Paclitaxel | Small molecule | — | — |
| Background | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |